Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Internal Medicine, Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA.
Leuk Lymphoma. 2023 Apr;64(4):874-883. doi: 10.1080/10428194.2023.2183730. Epub 2023 Mar 12.
We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose. The proportion of positive cellular response against the peptide pool covering the full-length Wuhan-Hu-1 spike protein was similar between untreated and treated CLL patients at all three timepoints. The cellular response to the mutated regions of BA.2 spike protein was lower than the response to the corresponding regions in the ancestral spike after the second dose, but this difference was eliminated after the third dose.
我们设计了一项前瞻性研究，以评估慢性淋巴细胞白血病（CLL）患者在接受基于 mRNA 的疫苗接种后针对 SARS-CoV-2 的武汉株和奥密克戎 BA.2 株的体液（使用替代病毒中和试验）和细胞（使用 IFN-γ ELISpot）免疫反应。与治疗后的 CLL 患者相比，未经治疗的 CLL 患者在第二次和第三次接种后以及第一次接种后 12 个月时针对武汉株和奥密克戎 BA.2 均表现出更高比例的功能性体液反应。在所有三个时间点，未经治疗和治疗的 CLL 患者针对全长武汉株刺突蛋白的肽池的阳性细胞反应比例相似。在第二次接种后，针对 BA.2 刺突蛋白突变区的细胞反应低于对原始刺突蛋白相应区域的反应，但在第三次接种后，这种差异消除。
